Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vilborg Sigurdardottir

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Diabetes Care|March 30, 2004
Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetesVilborg Sigurdardottir, Björn Fagerberg, Johannes Hulthe
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|August 23, 2012
Endothelial cell antibody-mediated rejection and successful retransplantation in a heart transplanted patientVilborg Sigurdardottir, Oscar Kolsrud, Nidia Hernandez, et al.
Atherosclerosis|February 24, 2006
Circulating oxidized low-density lipoprotein is associated with echolucent plaques in the femoral artery independently of hsCRP in 61-year-old menVilborg Sigurdardottir, Björn Fagerberg, John Wikstrand, et al.
Lakartidningen|October 27, 2012
[More heart transplantations than ever]Björn Kornhall, Johan Nilsson, Vilborg Sigurdardottir, et al.
ESC Heart Failure|January 8, 2021
Heart rate kinetics during standard cardiopulmonary exercise testing in heart transplant recipients: a longitudinal studyOliver Schumacher, Lukas D Trachsel, David Herzig, et al.
Biomarkers in Medicine|February 14, 2014
Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levelsFinn Gustafsson, Einar Gude, Vilborg Sigurdardottir, et al.
BMC Infectious Diseases|December 26, 2015
Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipientsInger Johansson, Rune Andersson, Vanda Friman, et al.
Clinical Transplantation|October 14, 2015
Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantationDorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, et al.
Therapeutic Drug Monitoring|April 18, 2014
CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipientsDorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, et al.
Plos One|August 28, 2018
Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiographyChristian Zanchin, Kyohei Yamaji, Carolin Rogge, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Diabetes Care|March 30, 2004
Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetesVilborg Sigurdardottir, Björn Fagerberg, Johannes Hulthe
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|August 23, 2012
Endothelial cell antibody-mediated rejection and successful retransplantation in a heart transplanted patientVilborg Sigurdardottir, Oscar Kolsrud, Nidia Hernandez, et al.
Atherosclerosis|February 24, 2006
Circulating oxidized low-density lipoprotein is associated with echolucent plaques in the femoral artery independently of hsCRP in 61-year-old menVilborg Sigurdardottir, Björn Fagerberg, John Wikstrand, et al.
Lakartidningen|October 27, 2012
[More heart transplantations than ever]Björn Kornhall, Johan Nilsson, Vilborg Sigurdardottir, et al.
ESC Heart Failure|January 8, 2021
Heart rate kinetics during standard cardiopulmonary exercise testing in heart transplant recipients: a longitudinal studyOliver Schumacher, Lukas D Trachsel, David Herzig, et al.
Biomarkers in Medicine|February 14, 2014
Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levelsFinn Gustafsson, Einar Gude, Vilborg Sigurdardottir, et al.
BMC Infectious Diseases|December 26, 2015
Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipientsInger Johansson, Rune Andersson, Vanda Friman, et al.
Clinical Transplantation|October 14, 2015
Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantationDorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, et al.
Therapeutic Drug Monitoring|April 18, 2014
CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipientsDorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, et al.
Plos One|August 28, 2018
Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiographyChristian Zanchin, Kyohei Yamaji, Carolin Rogge, et al.
Pageof 2